Mario Colucci Selected Research

Mario Colucci Research Topics

Disease

13	Thrombosis (Thrombus) 01/2021 - 08/2002
6	Sepsis (Septicemia) 01/2020 - 08/2010
5	Inflammation (Inflammations) 04/2020 - 08/2010
5	Hemorrhage 01/2020 - 07/2003
5	Thrombophilia 05/2017 - 12/2003
4	Venous Thromboembolism 11/2022 - 08/2010
3	Disseminated Intravascular Coagulation 09/2015 - 08/2010
2	Atrial Fibrillation 11/2022 - 02/2016
2	Hemophilia A (Haemophilia) 07/2020 - 01/2020
2	Multiple Organ Failure (MODS) 03/2012 - 08/2010
2	Activated Protein C Resistance (APC Resistance) 04/2006 - 12/2003
2	Hyperprothrombinemia 04/2006 - 03/2004
1	Hypoxia (Hypoxemia) 01/2021
1	Infections 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Pituitary ACTH Hypersecretion 05/2017
1	Stroke (Strokes) 09/2012
1	Edema (Dropsy) 09/2012
1	Brain Ischemia (Cerebral Ischemia) 09/2012
1	Constipation 08/2012
1	Obesity 08/2012
1	Binge Drinking 02/2012
1	Alcoholism (Alcohol Abuse) 02/2012
1	Necrosis 08/2010
1	Respiratory Hypersensitivity 01/2009
1	Fibrosis (Cirrhosis) 07/2003

Drug/Important Bio-Agent (IBA)

8	Thrombin FDA Link 11/2022 - 07/2003
6	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 01/2021 - 07/2003
4	Proteins (Proteins, Gene)FDA Link 04/2020 - 08/2010
3	AnticoagulantsIBA 11/2022 - 05/2017
3	FibrinIBA 01/2020 - 04/2006
3	Heparin (Liquaemin)FDA LinkGeneric 02/2016 - 08/2002
3	Histones (Histone)IBA 02/2016 - 08/2010
3	Antifibrinolytic Agents (Antifibrinolytics)IBA 03/2004 - 07/2003
2	apixabanIBA 11/2022 - 02/2016
2	Dabigatran FDA Link 11/2022 - 02/2016
2	RivaroxabanIBA 11/2022 - 02/2016
2	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 04/2020 - 02/2016
2	EnzymesIBA 01/2020 - 08/2010
2	Factor VIII (Coagulation Factor VIII)IBA 01/2020 - 05/2017
2	fibrin fragment D (D-dimer)IBA 01/2020 - 01/2019
2	PlasminogenIBA 02/2016 - 04/2006
2	Dacarbazine (DIC)FDA LinkGeneric 03/2012 - 08/2010
2	Prothrombin (Factor II)IBA 04/2006 - 03/2004
2	CarboxypeptidasesIBA 03/2004 - 07/2003
1	edoxabanIBA 11/2022
1	Angiotensin IIIBA 01/2021
1	CytokinesIBA 01/2021
1	Thromboplastin (Tissue Factor)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 07/2020
1	Choline (Choline Chloride)IBA 01/2020
1	CurcuminIBA 01/2020
1	Fibrinolysin FDA Link 01/2020
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2020
1	SilymarinIBA 01/2020
1	Tocopherols (Tocopherol)IBA 01/2020
1	AlbuminsIBA 01/2018
1	ThrombomodulinIBA 05/2017
1	GlucocorticoidsIBA 05/2017
1	AntithrombinsIBA 02/2016
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 04/2014
1	Glyburide (Glibenclamide)FDA LinkGeneric 09/2012
1	Sulfonylurea ReceptorsIBA 09/2012
1	Complement System Proteins (Complement)IBA 09/2012
1	Tissue Plasminogen Activator (Alteplase)FDA Link 09/2012
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 09/2012
1	Oxidopamine (6 Hydroxydopamine)IBA 08/2012
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 08/2012
1	Plasminogen Activator Inhibitor 1IBA 08/2012
1	NexusIBA 03/2012
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 03/2012
1	HMGB ProteinsIBA 03/2012
1	Biomarkers (Surrogate Marker)IBA 02/2012
1	ethyl glucuronideIBA 02/2012
1	Nuclear Proteins (Protein, Nuclear)IBA 08/2010
1	Adenosine (Adenocard)FDA LinkGeneric 01/2009
1	melagatranIBA 12/2007
1	Factor V (Coagulation Factor V)IBA 12/2003

Therapy/Procedure

1	Injections 09/2012
1	Thrombolytic Therapy 03/2012